Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: A one-year prospective study

Robert P. Finger, Peter Charbel Issa, Doris Hendig, Hendrik P N Scholl, Frank G. Holz

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the efficacy and safety of monthly intravitreal ranibizumab for the treatment of choroidal neovascularizations (CNV) secondary to angioid streaks (AS) in pseudoxanthoma elasticum (PXE). Design: Twelve-month prospective, open-label, uncontrolled, nonrandomized interventional clinical trial. Methods: In 7 patients, 1 eye with an active CNV was injected with 0.5 mg ranibizumab monthly over 1 year. Distance and reading visual acuity, reading speed, angiographic findings, and central retinal thickness (CRT) on optical coherence tomography were assessed at each visit. Central retinal light increment sensitivity (LIS) was assessed by microperimetry at baseline, at 6 months, and 3 to 4 months after the last injection. Results: Best-corrected visual acuity increased significantly from baseline to month 12 (20/63 or 61 ETDRS letters to 20/32 or 73 ETDRS letters; P =.012). The effect was maintained 3 months later (61 ETDRS letters to 72 ETDRS letters; P =.055). Reading acuity and speed could be maintained throughout the study. Central LIS improved (6.6 dB, SD ± 5.9 at baseline to 7.4 dB, SD ± 6.2 at last follow-up; P

Original languageEnglish (US)
Pages (from-to)695-703
Number of pages9
JournalAmerican Journal of Ophthalmology
Volume152
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Angioid Streaks
Pseudoxanthoma Elasticum
Choroidal Neovascularization
Reading
Photophobia
Prospective Studies
Visual Acuity
Optical Coherence Tomography
Safety
Injections
Ranibizumab
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum : A one-year prospective study. / Finger, Robert P.; Charbel Issa, Peter; Hendig, Doris; Scholl, Hendrik P N; Holz, Frank G.

In: American Journal of Ophthalmology, Vol. 152, No. 4, 10.2011, p. 695-703.

Research output: Contribution to journalArticle

Finger, Robert P. ; Charbel Issa, Peter ; Hendig, Doris ; Scholl, Hendrik P N ; Holz, Frank G. / Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum : A one-year prospective study. In: American Journal of Ophthalmology. 2011 ; Vol. 152, No. 4. pp. 695-703.
@article{d473599f8b3b4cc5a38459e5276796e3,
title = "Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: A one-year prospective study",
abstract = "Purpose: To evaluate the efficacy and safety of monthly intravitreal ranibizumab for the treatment of choroidal neovascularizations (CNV) secondary to angioid streaks (AS) in pseudoxanthoma elasticum (PXE). Design: Twelve-month prospective, open-label, uncontrolled, nonrandomized interventional clinical trial. Methods: In 7 patients, 1 eye with an active CNV was injected with 0.5 mg ranibizumab monthly over 1 year. Distance and reading visual acuity, reading speed, angiographic findings, and central retinal thickness (CRT) on optical coherence tomography were assessed at each visit. Central retinal light increment sensitivity (LIS) was assessed by microperimetry at baseline, at 6 months, and 3 to 4 months after the last injection. Results: Best-corrected visual acuity increased significantly from baseline to month 12 (20/63 or 61 ETDRS letters to 20/32 or 73 ETDRS letters; P =.012). The effect was maintained 3 months later (61 ETDRS letters to 72 ETDRS letters; P =.055). Reading acuity and speed could be maintained throughout the study. Central LIS improved (6.6 dB, SD ± 5.9 at baseline to 7.4 dB, SD ± 6.2 at last follow-up; P",
author = "Finger, {Robert P.} and {Charbel Issa}, Peter and Doris Hendig and Scholl, {Hendrik P N} and Holz, {Frank G.}",
year = "2011",
month = "10",
doi = "10.1016/j.ajo.2011.03.022",
language = "English (US)",
volume = "152",
pages = "695--703",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum

T2 - A one-year prospective study

AU - Finger, Robert P.

AU - Charbel Issa, Peter

AU - Hendig, Doris

AU - Scholl, Hendrik P N

AU - Holz, Frank G.

PY - 2011/10

Y1 - 2011/10

N2 - Purpose: To evaluate the efficacy and safety of monthly intravitreal ranibizumab for the treatment of choroidal neovascularizations (CNV) secondary to angioid streaks (AS) in pseudoxanthoma elasticum (PXE). Design: Twelve-month prospective, open-label, uncontrolled, nonrandomized interventional clinical trial. Methods: In 7 patients, 1 eye with an active CNV was injected with 0.5 mg ranibizumab monthly over 1 year. Distance and reading visual acuity, reading speed, angiographic findings, and central retinal thickness (CRT) on optical coherence tomography were assessed at each visit. Central retinal light increment sensitivity (LIS) was assessed by microperimetry at baseline, at 6 months, and 3 to 4 months after the last injection. Results: Best-corrected visual acuity increased significantly from baseline to month 12 (20/63 or 61 ETDRS letters to 20/32 or 73 ETDRS letters; P =.012). The effect was maintained 3 months later (61 ETDRS letters to 72 ETDRS letters; P =.055). Reading acuity and speed could be maintained throughout the study. Central LIS improved (6.6 dB, SD ± 5.9 at baseline to 7.4 dB, SD ± 6.2 at last follow-up; P

AB - Purpose: To evaluate the efficacy and safety of monthly intravitreal ranibizumab for the treatment of choroidal neovascularizations (CNV) secondary to angioid streaks (AS) in pseudoxanthoma elasticum (PXE). Design: Twelve-month prospective, open-label, uncontrolled, nonrandomized interventional clinical trial. Methods: In 7 patients, 1 eye with an active CNV was injected with 0.5 mg ranibizumab monthly over 1 year. Distance and reading visual acuity, reading speed, angiographic findings, and central retinal thickness (CRT) on optical coherence tomography were assessed at each visit. Central retinal light increment sensitivity (LIS) was assessed by microperimetry at baseline, at 6 months, and 3 to 4 months after the last injection. Results: Best-corrected visual acuity increased significantly from baseline to month 12 (20/63 or 61 ETDRS letters to 20/32 or 73 ETDRS letters; P =.012). The effect was maintained 3 months later (61 ETDRS letters to 72 ETDRS letters; P =.055). Reading acuity and speed could be maintained throughout the study. Central LIS improved (6.6 dB, SD ± 5.9 at baseline to 7.4 dB, SD ± 6.2 at last follow-up; P

UR - http://www.scopus.com/inward/record.url?scp=80053313612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053313612&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2011.03.022

DO - 10.1016/j.ajo.2011.03.022

M3 - Article

C2 - 21704964

AN - SCOPUS:80053313612

VL - 152

SP - 695

EP - 703

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -